Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis
Osteoporosis becomes a serious health threat for older postmenopausal women by predisposing them to an increased risk of fracture. Osteoporosis and associated fractures are an important cause of morbidity and mortality. Special attention is being paid to early detection, management, and treatment of...
Gespeichert in:
| Veröffentlicht in: | Indian journal of clinical biochemistry 2012-01, Vol.27 (1), p.90-93 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 93 |
|---|---|
| container_issue | 1 |
| container_start_page | 90 |
| container_title | Indian journal of clinical biochemistry |
| container_volume | 27 |
| creator | Jagtap, Vanita R. Ganu, Jayshree V. |
| description | Osteoporosis becomes a serious health threat for older postmenopausal women by predisposing them to an increased risk of fracture. Osteoporosis and associated fractures are an important cause of morbidity and mortality. Special attention is being paid to early detection, management, and treatment of postmenopausal osteoporosis in women. Biochemical markers can enable dynamic and rapid measurement of total body skeletal metabolism and will be clinically useful in the management of postmenopausal osteoporosis women (PMO) and also for assessing the effects of antiresorptive therapy. With this view, we planned to assess osteoclastic activity by determining urinary hydroxyproline in osteoporotic women. The aim of this study is to measure urinary hydroxyproline (expressed as mg of hydroxyproline/g of creatinine) and serum ascorbic acid in postmenopausal women with osteoporosis and without osteoporosis. These biochemical parameters were determined 3 months post antiresorptive therapy (alendronate + calcium + vitamin D) in postmenopausal osteoporosis patients. 60 postmenopausal women with osteoporosis in the age group 45–60 years and 60 healthy postmenopausal women (normal bone mineral density) in the same age group were included in the study. Urinary hydroxyproline levels were significantly increased (
P
|
| doi_str_mv | 10.1007/s12291-011-0185-4 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3286577</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714406196</galeid><sourcerecordid>A714406196</sourcerecordid><originalsourceid>FETCH-LOGICAL-c636t-92c6aeecc716ea6375a7c467209918d10ab8c8dd8519255488c31e771f7ce2953</originalsourceid><addsrcrecordid>eNp1klFv1SAUxxujcXP6AXwxjb7oQycHKJQXk5tluiVLZnR78IkwenrH0gsV2mX320vtnF6jIQQCv_PnnMO_KF4COQRC5PsElCqoCMyzqSv-qNgnSvKKcEof_9yTChTUe8WzlG4IYZxweFrsUUallNDsF9-Ouw7tWIauXPnRRUwhDqO7xfLiGqMZtmXw5WV03sRtebJtY7jbDjH0zmPpfPk5pHGDPgxmSqYvz9OIYQgxJJeeF0860yd8cb8eFJcfjy-OTqqz80-nR6uzygomxkpRKwyitRIEGsFkbaTlQlKiFDQtEHPV2KZtmxoUrWveNJYB5uQ7aZGqmh0UHxbdYbraYGvRj9H0eohuk3PWwTi9e-PdtV6HW81oI2ops8Dbe4EYvk-YRr1xyWLfG49hShqoZACU1CKjr_9Cb8IUfS5PK8o4o1zwDL1ZoLXpUTvfhfysnTX1SgLnRICapQ7_QeXR4sbZ4LFz-Xwn4N1OQGZGvBvXufNJn379ssvCwtr8FSli99AOIHq2jl6so7N19GwdPaf96s8-PkT88koG6AKkfOXXGH8X_3_VHwfazZU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>923432464</pqid></control><display><type>article</type><title>Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis</title><source>Springer Nature - Complete Springer Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Jagtap, Vanita R. ; Ganu, Jayshree V.</creator><creatorcontrib>Jagtap, Vanita R. ; Ganu, Jayshree V.</creatorcontrib><description>Osteoporosis becomes a serious health threat for older postmenopausal women by predisposing them to an increased risk of fracture. Osteoporosis and associated fractures are an important cause of morbidity and mortality. Special attention is being paid to early detection, management, and treatment of postmenopausal osteoporosis in women. Biochemical markers can enable dynamic and rapid measurement of total body skeletal metabolism and will be clinically useful in the management of postmenopausal osteoporosis women (PMO) and also for assessing the effects of antiresorptive therapy. With this view, we planned to assess osteoclastic activity by determining urinary hydroxyproline in osteoporotic women. The aim of this study is to measure urinary hydroxyproline (expressed as mg of hydroxyproline/g of creatinine) and serum ascorbic acid in postmenopausal women with osteoporosis and without osteoporosis. These biochemical parameters were determined 3 months post antiresorptive therapy (alendronate + calcium + vitamin D) in postmenopausal osteoporosis patients. 60 postmenopausal women with osteoporosis in the age group 45–60 years and 60 healthy postmenopausal women (normal bone mineral density) in the same age group were included in the study. Urinary hydroxyproline levels were significantly increased (
P
< 0.001) in PMO at baseline level as compared to control group. These levels were decreased significantly (
P
< 0.001) post therapy in PMO patients. Serum vitamin C levels were significantly decreased (
P
< 0.001) in PMO patients at baseline level as compared to controls. No significant change occurred of serum vitamin C level post therapy. Raised excretion of hydroxyproline at the baseline level might be due to increased degradation of collagen type I from the bone matrix in osteoporosis. Breakdown of collagen seems to be lowered as reflected by lowering of hydroxyproline excretion post antiresorptive therapy. Alteration in the concentration of this marker can be very well utilized to monitor the effectiveness of therapy. Thus simple, direct urinary assay to measure bone resorption is very useful in monitoring the therapy in PMO and may become an integral part of the management of osteoporosis.</description><identifier>ISSN: 0970-1915</identifier><identifier>EISSN: 0974-0422</identifier><identifier>DOI: 10.1007/s12291-011-0185-4</identifier><identifier>PMID: 23277718</identifier><language>eng</language><publisher>India: Springer-Verlag</publisher><subject>Alfacalcidol ; Amino acids ; Biochemistry ; Biomedical and Life Sciences ; Bone density ; Calcifediol ; Care and treatment ; Chemistry/Food Science ; Collagen ; Drug therapy ; Health aspects ; Life Sciences ; Menopause ; Microbiology ; Mortality ; Original ; Original Article ; Osteoporosis ; Pathology ; Physiological aspects ; Planning ; Postmenopausal women ; Urine ; Vitamin D ; Women</subject><ispartof>Indian journal of clinical biochemistry, 2012-01, Vol.27 (1), p.90-93</ispartof><rights>Association of Clinical Biochemists of India 2011</rights><rights>COPYRIGHT 2012 Springer</rights><rights>Association of Clinical Biochemists of India 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c636t-92c6aeecc716ea6375a7c467209918d10ab8c8dd8519255488c31e771f7ce2953</citedby><cites>FETCH-LOGICAL-c636t-92c6aeecc716ea6375a7c467209918d10ab8c8dd8519255488c31e771f7ce2953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286577/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286577/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23277718$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jagtap, Vanita R.</creatorcontrib><creatorcontrib>Ganu, Jayshree V.</creatorcontrib><title>Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis</title><title>Indian journal of clinical biochemistry</title><addtitle>Ind J Clin Biochem</addtitle><addtitle>Indian J Clin Biochem</addtitle><description>Osteoporosis becomes a serious health threat for older postmenopausal women by predisposing them to an increased risk of fracture. Osteoporosis and associated fractures are an important cause of morbidity and mortality. Special attention is being paid to early detection, management, and treatment of postmenopausal osteoporosis in women. Biochemical markers can enable dynamic and rapid measurement of total body skeletal metabolism and will be clinically useful in the management of postmenopausal osteoporosis women (PMO) and also for assessing the effects of antiresorptive therapy. With this view, we planned to assess osteoclastic activity by determining urinary hydroxyproline in osteoporotic women. The aim of this study is to measure urinary hydroxyproline (expressed as mg of hydroxyproline/g of creatinine) and serum ascorbic acid in postmenopausal women with osteoporosis and without osteoporosis. These biochemical parameters were determined 3 months post antiresorptive therapy (alendronate + calcium + vitamin D) in postmenopausal osteoporosis patients. 60 postmenopausal women with osteoporosis in the age group 45–60 years and 60 healthy postmenopausal women (normal bone mineral density) in the same age group were included in the study. Urinary hydroxyproline levels were significantly increased (
P
< 0.001) in PMO at baseline level as compared to control group. These levels were decreased significantly (
P
< 0.001) post therapy in PMO patients. Serum vitamin C levels were significantly decreased (
P
< 0.001) in PMO patients at baseline level as compared to controls. No significant change occurred of serum vitamin C level post therapy. Raised excretion of hydroxyproline at the baseline level might be due to increased degradation of collagen type I from the bone matrix in osteoporosis. Breakdown of collagen seems to be lowered as reflected by lowering of hydroxyproline excretion post antiresorptive therapy. Alteration in the concentration of this marker can be very well utilized to monitor the effectiveness of therapy. Thus simple, direct urinary assay to measure bone resorption is very useful in monitoring the therapy in PMO and may become an integral part of the management of osteoporosis.</description><subject>Alfacalcidol</subject><subject>Amino acids</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Bone density</subject><subject>Calcifediol</subject><subject>Care and treatment</subject><subject>Chemistry/Food Science</subject><subject>Collagen</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Life Sciences</subject><subject>Menopause</subject><subject>Microbiology</subject><subject>Mortality</subject><subject>Original</subject><subject>Original Article</subject><subject>Osteoporosis</subject><subject>Pathology</subject><subject>Physiological aspects</subject><subject>Planning</subject><subject>Postmenopausal women</subject><subject>Urine</subject><subject>Vitamin D</subject><subject>Women</subject><issn>0970-1915</issn><issn>0974-0422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1klFv1SAUxxujcXP6AXwxjb7oQycHKJQXk5tluiVLZnR78IkwenrH0gsV2mX320vtnF6jIQQCv_PnnMO_KF4COQRC5PsElCqoCMyzqSv-qNgnSvKKcEof_9yTChTUe8WzlG4IYZxweFrsUUallNDsF9-Ouw7tWIauXPnRRUwhDqO7xfLiGqMZtmXw5WV03sRtebJtY7jbDjH0zmPpfPk5pHGDPgxmSqYvz9OIYQgxJJeeF0860yd8cb8eFJcfjy-OTqqz80-nR6uzygomxkpRKwyitRIEGsFkbaTlQlKiFDQtEHPV2KZtmxoUrWveNJYB5uQ7aZGqmh0UHxbdYbraYGvRj9H0eohuk3PWwTi9e-PdtV6HW81oI2ops8Dbe4EYvk-YRr1xyWLfG49hShqoZACU1CKjr_9Cb8IUfS5PK8o4o1zwDL1ZoLXpUTvfhfysnTX1SgLnRICapQ7_QeXR4sbZ4LFz-Xwn4N1OQGZGvBvXufNJn379ssvCwtr8FSli99AOIHq2jl6so7N19GwdPaf96s8-PkT88koG6AKkfOXXGH8X_3_VHwfazZU</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Jagtap, Vanita R.</creator><creator>Ganu, Jayshree V.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>04Q</scope><scope>04W</scope><scope>3V.</scope><scope>7XB</scope><scope>88A</scope><scope>88I</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120101</creationdate><title>Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis</title><author>Jagtap, Vanita R. ; Ganu, Jayshree V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c636t-92c6aeecc716ea6375a7c467209918d10ab8c8dd8519255488c31e771f7ce2953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Alfacalcidol</topic><topic>Amino acids</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Bone density</topic><topic>Calcifediol</topic><topic>Care and treatment</topic><topic>Chemistry/Food Science</topic><topic>Collagen</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Life Sciences</topic><topic>Menopause</topic><topic>Microbiology</topic><topic>Mortality</topic><topic>Original</topic><topic>Original Article</topic><topic>Osteoporosis</topic><topic>Pathology</topic><topic>Physiological aspects</topic><topic>Planning</topic><topic>Postmenopausal women</topic><topic>Urine</topic><topic>Vitamin D</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jagtap, Vanita R.</creatorcontrib><creatorcontrib>Ganu, Jayshree V.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>India Database</collection><collection>India Database: Science & Technology</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Indian journal of clinical biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jagtap, Vanita R.</au><au>Ganu, Jayshree V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis</atitle><jtitle>Indian journal of clinical biochemistry</jtitle><stitle>Ind J Clin Biochem</stitle><addtitle>Indian J Clin Biochem</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>27</volume><issue>1</issue><spage>90</spage><epage>93</epage><pages>90-93</pages><issn>0970-1915</issn><eissn>0974-0422</eissn><abstract>Osteoporosis becomes a serious health threat for older postmenopausal women by predisposing them to an increased risk of fracture. Osteoporosis and associated fractures are an important cause of morbidity and mortality. Special attention is being paid to early detection, management, and treatment of postmenopausal osteoporosis in women. Biochemical markers can enable dynamic and rapid measurement of total body skeletal metabolism and will be clinically useful in the management of postmenopausal osteoporosis women (PMO) and also for assessing the effects of antiresorptive therapy. With this view, we planned to assess osteoclastic activity by determining urinary hydroxyproline in osteoporotic women. The aim of this study is to measure urinary hydroxyproline (expressed as mg of hydroxyproline/g of creatinine) and serum ascorbic acid in postmenopausal women with osteoporosis and without osteoporosis. These biochemical parameters were determined 3 months post antiresorptive therapy (alendronate + calcium + vitamin D) in postmenopausal osteoporosis patients. 60 postmenopausal women with osteoporosis in the age group 45–60 years and 60 healthy postmenopausal women (normal bone mineral density) in the same age group were included in the study. Urinary hydroxyproline levels were significantly increased (
P
< 0.001) in PMO at baseline level as compared to control group. These levels were decreased significantly (
P
< 0.001) post therapy in PMO patients. Serum vitamin C levels were significantly decreased (
P
< 0.001) in PMO patients at baseline level as compared to controls. No significant change occurred of serum vitamin C level post therapy. Raised excretion of hydroxyproline at the baseline level might be due to increased degradation of collagen type I from the bone matrix in osteoporosis. Breakdown of collagen seems to be lowered as reflected by lowering of hydroxyproline excretion post antiresorptive therapy. Alteration in the concentration of this marker can be very well utilized to monitor the effectiveness of therapy. Thus simple, direct urinary assay to measure bone resorption is very useful in monitoring the therapy in PMO and may become an integral part of the management of osteoporosis.</abstract><cop>India</cop><pub>Springer-Verlag</pub><pmid>23277718</pmid><doi>10.1007/s12291-011-0185-4</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0970-1915 |
| ispartof | Indian journal of clinical biochemistry, 2012-01, Vol.27 (1), p.90-93 |
| issn | 0970-1915 0974-0422 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3286577 |
| source | Springer Nature - Complete Springer Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Alfacalcidol Amino acids Biochemistry Biomedical and Life Sciences Bone density Calcifediol Care and treatment Chemistry/Food Science Collagen Drug therapy Health aspects Life Sciences Menopause Microbiology Mortality Original Original Article Osteoporosis Pathology Physiological aspects Planning Postmenopausal women Urine Vitamin D Women |
| title | Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A59%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Antiresorptive%20Therapy%20on%20Urinary%20Hydroxyproline%20in%20Postmenopausal%20Osteoporosis&rft.jtitle=Indian%20journal%20of%20clinical%20biochemistry&rft.au=Jagtap,%20Vanita%20R.&rft.date=2012-01-01&rft.volume=27&rft.issue=1&rft.spage=90&rft.epage=93&rft.pages=90-93&rft.issn=0970-1915&rft.eissn=0974-0422&rft_id=info:doi/10.1007/s12291-011-0185-4&rft_dat=%3Cgale_pubme%3EA714406196%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=923432464&rft_id=info:pmid/23277718&rft_galeid=A714406196&rfr_iscdi=true |